AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01771042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary weight loss at 25% energy deficit
Description: Dietary weight loss at 25% energy deficit. Dietary macronutrient content will comprise 25% protein, 30% fat and 45% carbohydrate.
Study NCT00808561 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: Alternative Fistula
Description: Performing other autogenous AV fistulas which include various options such as brachiocephalic AV fistula, basilic or brachial vein transpositions or a variety of other strategies to maintain a primary access. The advantage would be to maintain an autogenous all venous access with less risk of infection and thrombosis.
Study NCT00808561 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: Forearm AV Graft
Description: a) ePTFE (polytetrafluoroethylene) bridge AV graft typically anastomosed in the proximal forearm to the radial or brachial artery and to an antecubital vein. The advantages include a quick maturation of 2-3 weeks, excellent flow rates and high technical success rates. Although secondary patency rates approach 80% at one year postoperatively, disadvantages include a more involved surgical procedure, a lower primary patency than a well functioning AV fistula, and higher revision and infection rates.4, 5
Study NCT00579098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 80 mg tablet taken by mouth daily for 90 days
Study NCT00579098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken by mouth once daily for 90 days
Study NCT02386631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Made Orthotic
Description: Provides longitudinal arch support
Study NCT02969330 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulator
Study NCT02969330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: 300ml tap water with 75g glucose
Study NCT02969330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 300ml tap water with 75g glucose
Study NCT02436681 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MIROMESH
Study NCT02121522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807
Description: twice daily
Study NCT00819299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcuFocus Corneal Inlay ACI 7000PDT
Description: corneal inlay
Study NCT02001103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Pills of memantine, including 5 or 10 mg, all prepared in the same capsules as used in the placebo arm.~The Memantine 10 mg intervention arm will take 1 capsule of memantine and 1 capsule of placebo going into week 3.
Study NCT02001103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules with starch inside manufactured using the same capsules as used in the other 2 arms.
Study NCT03537573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care/Guideline
Description: The Usual Care group (also known as the Guideline group) follows the recent CDC guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy. Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
Study NCT03537573 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care/Guideline
Description: The Usual Care group (also known as the Guideline group) follows the recent CDC guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy. Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
Study NCT03537573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opioid Justification
Description: Providers will be required asked to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition. The provider will be notified that the justification provided will be visible in the Epic EHR. The provider has the option of entering a justification or not. If no justification is entered, nothing will be entered into the record (i.e., the Opioid Justification area in the encounter record will be left blank). The provider does not need to enter a justification if they choose to cancel the opioid prescription.
Study NCT03537573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Comparison
Description: Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids or acute pain who transition to chronic opioid therapy (> 3 months). Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions, unsafe opioid prescribing, and transition to chronic opioid therapy (> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain. Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
Study NCT02001103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules with starch inside manufactured using the same capsules as used in the other 2 arms.
Study NCT02526446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure
Description: The intervention consists of a total of 28 hours over a period of 8 weeks:~i) Individual learning and practice: The training session will be one-on-one provided twice a week for two consecutive weeks (5 hours) in the participant's home.~ii) Self-practice at home: From 3rd to 8th week, participant will engage in self-administered acupressure at home for 15 minutes twice a day for 6 weeks (21 hours).~iii) Home follow-up: During the 3rd and 4th week (i.e. after the 2-week training session), a 1-hour home visit will be conducted for reinforcement of learning and self-practice by the same team of trainers once a week for 2 weeks (2 hours).
Study NCT02526446 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: wait-list control
Description: The control group will receive a wait-list control condition (the same self-administered acupressure intervention but after the intervention group has completed the treatment condition).
Study NCT00446420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol, midazolam, fentanyl
Description: All drugs administered in doses according to anaesthetists' discretion during sedation for colonoscopy
Study NCT03476278 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Postoperative questionnaire, and records of complications in the peri-operative period
Study NCT02279446 — intervention group
Intervention type: OTHER
Intervention: Intermediate Visual acuity (IVA) assessment
Description: Intermediate visual acuity (IVA) will be assessed with the Intermediate Visual acuity chart which is similar to the prevalent Jaeger chart. It consists of short blocks of text in various type sizes.The computer screen is set at a specific reading distance (1 meter) and the patient is asked to read the passage with the smallest type he/she can see. According to the smallest text he/she can read, IVA is classified from IVA1 (which is considered the equivalent of 20/20 distance visual acuity) to IVA5
Study NCT04020588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: Will be administered for 6 weeks
Study NCT04020588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Will be administered for 6 weeks
Study NCT04020588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline 100mg
Description: Will be administered for 6 weeks
Study NCT03750461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesh Implantation
Description: Implantation of permanent mesh (BARD Soft Mesh) into the abdominal wall for reinforcement to prevent hernia formation
Study NCT01511965 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: autologous (cellular therapy)
Description: The skin sample, the preparation and implementation of the epidermal cells, are conducted on one day. A review of selected lesions is performed and a photograph. Second, are performed successively in a single day the collection of thin skin, preparing the cell suspension, a desepidermisation laser Erbium: YAG lesions of vitiligo to be grafted, and applicated.
Study NCT02406183 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: The SBRT dose will be escalated in 3 steps as described above and will be given on d39, d41 and d43
Study NCT02406183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3mg/kg will be given IV on d1, d22, d43 and d64
Study NCT03841448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% NaCl) matching volume of cemdisiran doses were administered SC.
Study NCT03841448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: Cemdisiran was administered by SC injection.
Study NCT03841448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cemdisiran
Description: Cemdisiran was administered by SC injection.
Study NCT01811225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Progesterone
Description: The low progesterone dose is seven days of placebo Tri-sprintec + placebo generic Prometrium twice a day (7AM and 7PM).
Study NCT01811225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose Progesterone
Description: The high progesterone dose is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice a day (7AM and 7PM).
Study NCT02910115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold laparotomy sponges
Description: Cold laparotomy sponges are lap sponges that are saturated in sterile, iced normal saline
Study NCT02910115 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pitocin
Description: Pitocin is administered intravenously according to the usual protocol.
Study NCT02910115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitocin
Description: Pitocin is administered intravenously according to the usual protocol.
Study NCT04612439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VABB Elite 10G
Description: If the biopsy device is a vacuum-assisted Elite 10G needle, insert the needle groove into the mass and rotate to cut the biopsy tissue one circle
Study NCT04612439 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BARD 14G CNB
Description: If the biopsy device is a BARD 14G hollow core needle, insert the needle to the edge of the mass and pull the trigger in different directions to eject the needle to retrieve the material
Study NCT02645201 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gastrus
Description: to compare Gastrus 4x108 tbl twice a day to placebo tbl
Study NCT02645201 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: to compare Gastrus 4x108 tbl twice a day to placebo tbl
Study NCT02397031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: weekly psychotherapy sessions for 10 weeks (120 min each)
Study NCT02397031 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interpersonal effectiveness
Description: weekly psychotherapy sessions for 10 weeks (120 min each)
Study NCT02135770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: 10 unit/kgBW/hour continuous infusion for 72 hours
Study NCT03088371 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine 0.25%
Description: For psoas sciatic block.
Study NCT03088371 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pajunk Needle
Description: For local anaesthesia application in psoas sciatic block
Study NCT03088371 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Portex combined spinal epidural kit
Description: For combined spinal epidural anaesthesia
Study NCT03088371 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine 1%
Description: For psoas sciatic block.
Study NCT03088371 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine 0.5%
Description: For spinal anaesthesia in combined spinal epidural anaesthesia.
Study NCT03884101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
Study NCT03884101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.
Study NCT03884101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.
Study NCT01313676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate/vilanterol
Description: 100/25mcg given once daily via novel dry powder inhaler
Study NCT03884101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
Study NCT03995979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4 Day Protein Restricted Diet
Description: Subjects will follow a 4 day protein restricted diet using Scandishake® mixed with almond milk which will be provided. They may also drink water. No food, other beverages, or alcohol may be consumed. The amount of diet to be consumed will be calculated for each patient based upon resting energy expenditures plus additional energy needs. These will be consumed by the study subjects at home in an unrestricted manner, in that they may be consumed at any point of time in the day.
Study NCT00442546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: 300 mg/day (double blind)
Study NCT00442546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03088371 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine 2 %
Description: For psoas sciatic block in the post-operative period
Study NCT03088371 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine 0.125 %
Description: For combined spinal epidural in the post-operative period.
Study NCT04686695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: taVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 20 Hz with pulse duration ≤ 1 ms, for 30min,administered twice daily.
Study NCT00287365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ozone
Description: 2 hour exposure to 0.4 ppm ozone
Study NCT04401826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tunneling micro-surgical crown lengthening approach using piezo-surgery
Description: excess gingiva is eliminated. 2 mm bone is removed from CEJ-bone crest with piezo surgery via tunneling
Study NCT04401826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-surgical crown lengthening approach using Piezosurgery
Description: excess gingiva is eliminated. 2 mm bone is removed from CEJ-bone crest with piezo surgery with conventional flap elevation.
Study NCT03788629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Talocrural joint MWM mobilization
Description: There were two groups for this study. In addition to Bobath Concept, talocrural joint mobilization was performed.
Study NCT03788629 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subtalar joint MWM mobilization
Description: There were two groups for this study. In addition to treatment of control group, subtalar joint mobilization was performed.
Study NCT02994069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin
Study NCT02994069 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: XRT
Description: Radiation Therapy
Study NCT01313676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate
Description: 100mcg given once daily via novel dry powder inhaler
Study NCT01313676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilanterol
Description: 25mcg given once daily via novel dry powder inhaler
Study NCT02502162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDN
Study NCT02502162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study NCT02311959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nipple sparing mastectomy
Description: Standardized surgical procedure by :~* Nipple sparing mastectomy with nipple core histopathology.~* Immediate breast reconstruction (flap and/or implant).~* +/- lymph node evaluation (sentinel node procedure or axillary dissection).
Study NCT01909453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: LGX818- Orally 100 mg and 50 mg capsules
Study NCT02642302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT With 60 sec Rest
Description: 30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 60 seconds rest on VO2Max and aerobic/ anaerobic performance
Study NCT02642302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT With120 sec Rest
Description: 30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 120 seconds rest on VO2Max and aerobic/ anaerobic performance
Study NCT02642302 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Continuous exercise at 50-55% VO2Max with similar total work of interval training
Study NCT02451943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV
Study NCT02451943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered IV
Study NCT02451943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Administered IV
Study NCT02451943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT03401385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan (Dato-DXd)
Description: A total anti-TROP2 antibody and MAAA-1181a
Study NCT03401385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid Containing Mouthwash
Description: A mouthwash containing a steroid ingredient administered in sub-study
Study NCT03401385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Steroid Containing Mouthwash
Description: A mouthwash containing a non-steroid ingredient administered in sub-study
Study NCT01922570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutrition
Description: comparion of enteral versus enteral and supplemental parenteral nutrition
Study NCT03416218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prognosis
Description: Prognosis will be a single-player 2D, digital simulation game and supporting multimedia website. Players are situated as a major official of Hexacago, and tasks them with managing the city's finances, education levels, and health concerns to lower rates of teenage pregnancy and sexually transmitted infections. In the game Prognosis, player dispatches professionals from a variety of fields to different neighborhoods around the city, observing the effects of their resource allocation decisions across multiple systems over many in-game months. The supporting multimedia website will house curriculum and learning tools to support the learning objectives of Prognosis.
Study NCT03720015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Physical exercise controlled program supervised by an accredited exercise specialist
Study NCT03720015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional management
Description: Nutritional management controlled by a PhD clinical and sport nutrition specialist
Study NCT00535197 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of autologous CD34+ stem cells into middle cerebral artery
Description: intra-arterial infusion into ipsilateral MCA, via trans-femoral approach